Evaluating a radiotherapy deep learning synthetic CT algorithm for PET-MR attenuation correction in the pelvis
-
Published:2024-01-29
Issue:1
Volume:11
Page:
-
ISSN:2197-7364
-
Container-title:EJNMMI Physics
-
language:en
-
Short-container-title:EJNMMI Phys
Author:
Wyatt Jonathan J.ORCID, Kaushik Sandeep, Cozzini Cristina, Pearson Rachel A., Petrides George, Wiesinger Florian, McCallum Hazel M., Maxwell Ross J.
Abstract
Abstract
Background
Positron emission tomography–magnetic resonance (PET-MR) attenuation correction is challenging because the MR signal does not represent tissue density and conventional MR sequences cannot image bone. A novel zero echo time (ZTE) MR sequence has been previously developed which generates signal from cortical bone with images acquired in 65 s. This has been combined with a deep learning model to generate a synthetic computed tomography (sCT) for MR-only radiotherapy. This study aimed to evaluate this algorithm for PET-MR attenuation correction in the pelvis.
Methods
Ten patients being treated with ano-rectal radiotherapy received a $$^{18}$$
18
F-FDG-PET-MR in the radiotherapy position. Attenuation maps were generated from ZTE-based sCT (sCTAC) and the standard vendor-supplied MRAC. The radiotherapy planning CT scan was rigidly registered and cropped to generate a gold standard attenuation map (CTAC). PET images were reconstructed using each attenuation map and compared for standard uptake value (SUV) measurement, automatic thresholded gross tumour volume (GTV) delineation and GTV metabolic parameter measurement. The last was assessed for clinical equivalence to CTAC using two one-sided paired t tests with a significance level corrected for multiple testing of $$p \le 0.05/7 = 0.007$$
p
≤
0.05
/
7
=
0.007
. Equivalence margins of $$\pm 3.5\%$$
±
3.5
%
were used.
Results
Mean whole-image SUV differences were −0.02% (sCTAC) compared to −3.0% (MRAC), with larger differences in the bone regions (−0.5% to −16.3%). There was no difference in thresholded GTVs, with Dice similarity coefficients $$\ge 0.987$$
≥
0.987
. However, there were larger differences in GTV metabolic parameters. Mean differences to CTAC in $${\mathrm {SUV}}_{\max}$$
SUV
max
were $$1.0 \pm 0.8\%$$
1.0
±
0.8
%
(± standard error, sCTAC) and $$-4.6 \pm 0.9\%$$
-
4.6
±
0.9
%
(MRAC), and $$1.0 \pm 0.7\%$$
1.0
±
0.7
%
(sCTAC) and $$-4.3 \pm 0.8\%$$
-
4.3
±
0.8
%
(MRAC) in $${\mathrm {SUV}}_{\rm mean}$$
SUV
mean
. The sCTAC was statistically equivalent to CTAC within a $$\pm 3.5\%$$
±
3.5
%
equivalence margin for $${\mathrm {SUV}}_{\max}$$
SUV
max
and $${\mathrm {SUV}}_{\rm mean}$$
SUV
mean
($$p = 0.007$$
p
=
0.007
and $$p = 0.002$$
p
=
0.002
), whereas the MRAC was not ($$p = 0.88$$
p
=
0.88
and $$p = 0.83$$
p
=
0.83
).
Conclusion
Attenuation correction using this radiotherapy ZTE-based sCT algorithm was substantially more accurate than current MRAC methods with only a 40 s increase in MR acquisition time. This did not impact tumour delineation but did significantly improve the accuracy of whole-image and tumour SUV measurements, which were clinically equivalent to CTAC. This suggests PET images reconstructed with sCTAC would enable accurate quantitative PET images to be acquired on a PET-MR scanner.
Publisher
Springer Science and Business Media LLC
Reference37 articles.
1. Leibfarth S, Simoncic U, Mönnich D, Welz S, Schmidt H, Schwenzer N, Zips D, Thorwarth D. Analysis of pairwise correlations in multi-parametric PET/MR data for biological tumor characterization and treatment individualization strategies. Eur J Nucl Med Mol Imaging. 2016;43(7):1199–208. 2. Catalano OA, Lee SI, Parente C, Cauley C, Furtado FS, Striar R, Soricelli A, Salvatore M, Li Y, Umutlu L, Cañamaque LG, Groshar D, Mahmood U, Blaszkowsky LS, Ryan DP, Clark JW, Wo J, Hong TS, Kunitake H, Bordeianou L, Berger D, Ricciardi R, Rosen B. Improving staging of rectal cancer in the pelvis: the role of PET/MRI. Eur J Nucl Med Mol Imaging. 2021;48(4):1235–45. https://doi.org/10.1007/s00259-020-05036-x. 3. Amorim BJ, Hong TS, Blaszkowsky LS, Ferrone CR, Berger DL, Bordeianou LG, Ricciardi R, Clark JW, Ryan DP, Wo JY, Qadan M, Vangel M, Umutlu L, Groshar D, Cañamaques LG, Gervais DA, Mahmood U, Rosen BR, Catalano OA. Clinical impact of PET/MR in treated colorectal cancer patients. Eur J Nucl Med Mol Imaging. 2019;46(11):2260–9. https://doi.org/10.1007/s00259-019-04449-7. 4. Fiorentino A, Laudicella R, Ciurlia E, Annunziata S, Lancellotta V, Mapelli P, Tuscano C, Caobelli F, Evangelista L, Marino L, Quartuccio N, Fiore M, Borghetti P, Chiaravalloti A, Ricci M, Desideri I, Alongi P. Positron emission tomography with computed tomography imaging (PET/CT) for the radiotherapy planning definition of the biological target volume: PART 2. Crit Rev Oncol Hematol. 2019;139:117–24. https://doi.org/10.1016/j.critrevonc.2019.03.008. 5. Couwenberg AM, Burbach JPM, Berbee M, Lacle MM, Arensman R, Raicu MG, Wessels FJ, Verdult J, Roodhart J, Reerink O, Hoendervangers S, Buijsen J, Grabsch HI, Pronk A, Consten ECJ, Smits AB, Heikens JT, Appelt AL, van Grevenstein WMU, Verkooijen HM, Intven MPW. Efficacy of dose-escalated chemoradiation on complete tumor response in patients with locally advanced rectal cancer (RECTAL-BOOST): a phase 2 randomized controlled trial. Int J Radiat Oncol Biol Phys. 2020;108(4):1008–18. https://doi.org/10.1016/j.ijrobp.2020.06.013.
|
|